Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

(2016) Laura C Cappelli et al.   ANNALS OF THE RHEUMATIC DISEASES

Immune-Related Adverse Events From Immune Checkpoint Inhibitors

(2016) KA Marrone et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection

(2015) Eoin F. McKinney et al.   NATURE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

(2015) Isabelle Le Mercier et al.   Frontiers in Immunology

Balance and Imbalance in the Immune System: Life on the Edge

(2014) Suzanne L. Topalian et al.   IMMUNITY

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY